Transpire Bio
Clinical-stage, US-based biopharmaceutical company focused on developing inhaled therapeutics and delivery platforms. Operates R&D, pilot cGMP and expanding commercial manufacturing facilities in the US. Activities include in‑house drug development across pulmonary, CNS, oncology and metabolic indications, co-development and licensing partnerships, ANDA/complex generics development, and commercialization partnerships.
Industries
Nr. of Employees
medium (51-250)
Transpire Bio
Products
Inhaled PDE4 inhibitor programs for interstitial lung disease (IPF/ILD)
Multi-asset clinical-stage programs applying inhaled PDE4 inhibitors to address idiopathic pulmonary fibrosis and related interstitial lung diseases.
Inhaled high‑potency cannabinoid formulation (CNS and oncology applications)
Clinical-grade, fully synthetic high‑potency inhaled cannabinoid formulation being developed as a multi‑indication platform (CNS disorders, glioblastoma and other oncology indications).
Inhalable GLP-1 program (obesity and diabetes)
Preclinical program developing an inhalable GLP‑1 formulation and device intended for faster onset, short-acting maintenance therapy.
Early-entry inhaled asthma/COPD generic therapies
Development of difficult-to-replicate inhaled generic products intended for early market entry in asthma and COPD.
Springboard
A proprietary inhalation delivery platform designed to deliver established multi-billion-dollar molecule franchises with applications in PAH, IPF, and ILD.
CBD formulation platform
A fully-developed CBD formulation platform with multiple clinical applications including CNS disorders and oncology applications.
Inhaled PDE4 inhibitor programs for interstitial lung disease (IPF/ILD)
Multi-asset clinical-stage programs applying inhaled PDE4 inhibitors to address idiopathic pulmonary fibrosis and related interstitial lung diseases.
Inhaled high‑potency cannabinoid formulation (CNS and oncology applications)
Clinical-grade, fully synthetic high‑potency inhaled cannabinoid formulation being developed as a multi‑indication platform (CNS disorders, glioblastoma and other oncology indications).
Inhalable GLP-1 program (obesity and diabetes)
Preclinical program developing an inhalable GLP‑1 formulation and device intended for faster onset, short-acting maintenance therapy.
Early-entry inhaled asthma/COPD generic therapies
Development of difficult-to-replicate inhaled generic products intended for early market entry in asthma and COPD.
Springboard
A proprietary inhalation delivery platform designed to deliver established multi-billion-dollar molecule franchises with applications in PAH, IPF, and ILD.
CBD formulation platform
A fully-developed CBD formulation platform with multiple clinical applications including CNS disorders and oncology applications.
Services
Strategic co-development and licensing arrangements to apply inhalation platforms to partner compounds and accelerate clinical development.
Development of difficult-to-replicate inhaled generic therapies and pursuit of regulatory filings and commercialization through licensing.
Internal R&D and clinical development of inhaled therapeutic assets across pulmonary, CNS, oncology and metabolic indications.
In-house pilot-scale cGMP capabilities supporting formulation development, device integration and clinical supply manufacturing.
Strategic co-development and licensing arrangements to apply inhalation platforms to partner compounds and accelerate clinical development.
Development of difficult-to-replicate inhaled generic therapies and pursuit of regulatory filings and commercialization through licensing.
Internal R&D and clinical development of inhaled therapeutic assets across pulmonary, CNS, oncology and metabolic indications.
In-house pilot-scale cGMP capabilities supporting formulation development, device integration and clinical supply manufacturing.
Expertise Areas
- Inhalation formulation development
- Inhalation device and drug–device combination development
- Clinical trial execution for inhaled therapeutics
- cGMP manufacturing for inhaled products
Key Technologies
- Dry powder inhaler (DPI) platforms
- Metered-dose inhaler (MDI) platforms
- Soft-mist inhaler platforms
- Clinical-grade high-payload inhalation formulations
News & Updates
U.S. FDA completed a pre-approval inspection at a manufacturing facility; the company received an Establishment Inspection Report (EIR) indicating cGMP compliance with a Voluntary Action Indicated (VAI) classification.
Announcement of completion of first human dosing in a clinical trial for an inhaled asthma and COPD program.
Definitive agreements announced to develop inhaled respiratory products with external manufacturing and formulation partners, covering multiple device and formulation technologies.
Entered exclusive license agreement to develop, manufacture and commercialize an investigational PDE4 inhibitor for respiratory diseases (territorial exclusions disclosed in announcement).
U.S. FDA granted orphan drug designation to two inhaled development programs targeting rare diseases (one in pulmonary fibrosis and one in glioblastoma).
Announcements describing expansion of R&D and commercial manufacturing footprint in Florida to support growth and production capacity.
U.S. FDA completed a pre-approval inspection at a manufacturing facility; the company received an Establishment Inspection Report (EIR) indicating cGMP compliance with a Voluntary Action Indicated (VAI) classification.
Announcement of completion of first human dosing in a clinical trial for an inhaled asthma and COPD program.
Definitive agreements announced to develop inhaled respiratory products with external manufacturing and formulation partners, covering multiple device and formulation technologies.
Entered exclusive license agreement to develop, manufacture and commercialize an investigational PDE4 inhibitor for respiratory diseases (territorial exclusions disclosed in announcement).
U.S. FDA granted orphan drug designation to two inhaled development programs targeting rare diseases (one in pulmonary fibrosis and one in glioblastoma).
Announcements describing expansion of R&D and commercial manufacturing footprint in Florida to support growth and production capacity.